Close
05-22

Celartics Biopharma's dendritic cell-based vaccine against COVID-19 infection found to efficiently produce viral antigen-specific T lymphocytes

Results from ongoing study suggest the major role of Celartics' Cov-DCVax in preventing viral infection of COVID-19 and in controlling progression of the virus-associated diseasesBeijing, May 22, 2020, Celartics Biopharma announced today the filing of a patent application covering a novel dendritic cell (DC)-based vaccine, Cov-DCVax, to fight viral infection of COVID-19. The results, led by Celart

ページあたり10アイテム(ページ1 / 1)合計4アイテム

© 著作権 2009-2019 ネットワーク情报      お問い合わせください   SiteMap